Acadia Pharmaceuticals Inc (ACAD) saw an uptrend of 1861589% in the recent trading with $2130000.0 being its most recent. The current price level -10.82% lower than the highest price of $25.23 marked by the stock while trading over the past 52-weeks, whereas it is 67.91% higher than the lowest price of $13.40 the company dropped to over past 52-weeks. The latest news story on ACAD appeared in (Business Wire) under the title “Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers” on Today.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 16 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.85 for the stock.
Acadia Pharmaceuticals Inc Earnings – What Happened With ACAD
Coming around sales and income figures on ACAD Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Acadia Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 167.12 million. ACAD does have institutional investors; and they hold 103.73% of the stock.
As on 2024-06-30, BAKER BROS. ADVISORS LP was the top most holder in Acadia Pharmaceuticals Inc (NASDAQ:ACAD) with an ownership of 42.88 million shares of the company or 25.9001 of the stake worth $696.77 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 8.2827 of the outstanding shares. Its stake is worth $222.82 million for having 13.71 million shares in hand.
RTW INVESTMENTS, LP also came holding a key position in the company during the recent quarter and it now holds 8.2799 of the outstanding shares. With this there are now 430.0 institutions which have possession in ACAD’s shares.
Key Metrics forACAD
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Acadia Pharmaceuticals Inc has a debt to equity ratio of 0.07.
Technical Analysis of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Acadia Pharmaceuticals Inc (ACAD), we notice that the stock’s 20-day average volume is at 1,801,755 shares and 100% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 2,201,732 shares. And to end, ACAD’s 100-day average volume is 1,983,486 shares with 100% of the long-term indicators pointing towards Buy for the stock.
